GSK Plc has raised its revenue forecast for 2024 on the back of a strong first quarter for its shingles and respiratory syncytial virus (RSV) vaccines and a recently launched treatment for myelofibrosis patients with anaemia. Together with high demand for the respiratory medicine Trelegy, group turnover is now expected to rise towards the upper end of the 5% to 7% range. At a press briefing on 1 May, Emma Walmsley, the chief executive, spoke confidently about the company’s continued pipeline progress.
